Pathogenic yeasts: Candida albicans & C. glabrata

Our research topics are:

  • Molecular biology of human pathogenic fungi
  • Functional genomics
  • Host/pathogen interactions
  • Metal acquisition
  • Intracellular survival
  • Invasion mechanisms
  • Microevolution
  • Morphology
  • Mode of action of antifungal agents

Human pathogenic fungi frequently cause infections of the skin and mucosa, however, they are also capable of causing severe, life threatening mycoses.

The Department of Microbial Pathogenicity Mechanisms (MPM) investigates infections caused by human pathogenic fungi. Research is focused on the pathogenesis of mycoses due to yeasts such as Candida albicans or C. glabrata. C. albicans is regarded as the most important of all medically relevant yeasts and is an extremely successful pathogen in humans. C. glabrata is closely related to the non-pathogenic baker’s yeast Saccharomyces cerevisiae. However, in many cases C. glabrata is the second most prevalent yeast pathogen in humans after C. albicans.

In contrast to most pathogenic fungi in humans such as Aspergillus fumigatus, Cryptococcus neoformans, or Histoplasma capsulatum, which are found in the environment, C. albicans and C. glabrata belong to the normal microflora of mucosal surfaces and are regarded as harmless commensals in most circumstances. In fact, most humans are probably colonized with these yeasts. An intact immune system and a balanced microbial flora are normally sufficient to protect the individual from Candida infections. However, certain critical events such as extensive antibacterial treatment or dysfunction of the immune system may enable these fungi to overgrow the microbial flora on mucosal surfaces.

Using cellular, microbial, molecular and biochemical methods and C. albicans or C. glabrata as model organisms, the goal of our research is to identify factors which fungal pathogens need to cause diseases. In addition to these efforts to increase our understanding of the basics of pathogenesis of fungal infections, we also seek to identify new biomarkers for diagnostic approaches and potential targets for antimycotic drug development.

The department MPM closely cooperates with the research group Microbial Immunology (MI)  and the Emmy Noether Junior Research group Adaptive Pathogenicity Strategies (APS), which develop and use in vivo infection models and investigate immunotherapies and interactions with the microbiota, in order to understand and prevent the pathogenesis of human pathogenic fungi.

Team

Bernhard Hube
Head
Sascha Brunke
Deputy head of department

Publications

Allert S, Schulz D, Kämmer P, Großmann P, Wolf T, Schäuble S, Panagiotou G, Brunke S, Hube B (2022) From environmental adaptation to host survival: Attributes that mediate pathogenicity of Candida auris. Virulence 13(1), 191-214.
Li XV, Leonardi I, Putzel GG, Semon A, Fiers WD, Kusakabe T, Lin WY, Gao IH, Doron I, Gutierrez-Guerrero A, DeCelie MB, Carriche GM, Mesko M, Yang C, Naglik JR, Hube B, Scherl EJ, Iliev ID (2022) Immune regulation by fungal strain diversity in inflammatory bowel disease. Nature 603(7902), 672-678.
Richardson JP, Brown R, Kichik N, Lee S, Priest E, Mogavero S, Maufrais C, Wickramasinghe DN, Tsavou A, Kotowicz NK, Hepworth OW, Gallego-Cortés A, Ponde NO, Ho J, Moyes DL, Wilson D, D'Enfert C, Hube B, Naglik JR (2022) Candidalysins are a new family of cytolytic fungal peptide toxins. mBio 13(1), e0351021.